Skip to main content

Table 1 Summary of the clinical parameters of patients with Crohn's disease

From: Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease

 

Responders

Non-responders

Responders

Non-responders

 
 

Test cohort

Validation cohort

Difference

At baseline

14

6

13

7

 

Gender (male/female)

8/6

4/3

8/5

4/4

 

Age (years)

36.2±14.6

36±15.4

26.8±8.7

30.2±5.1

Non-significant

CDAI

319.6±41.3

351.5±33.1

338.3±61.7

370.7±48.1

Non-significant

CRP (mg/ml)

22.7±20.2

13.5±28.9

27.2±36.2

16.5±11.6

Non-significant

Hemoglobin (g/l)

125.1±17.6

120.6±27.6

130±17.9

127±12

Non-significant

Leukocytes(g/l)

9±3.3

8±3.1

7.5±2.3

9.2±2.8

Non-significant

Neutrophils (%)

70±8.9

74.5±8.9

74±8.1

72.8±5.7

Non-significant

  1. CDAI, Crohn's disease activity index; CRP, C-reactive protein. Data are shown as mean ±SD.